Pfizer hires ex-FDA drug chief
The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...
Each year, flu vaccines are tailored to match the most prevalent virus strains expected to circulate. Without an official ...
SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for ...
Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
Pfizer has ended the global commercialisation of its haemophilia B (factor IX deficiency) gene therapy Beqvez, citing soft demand for gene therapies among haemophilia patients and physicians.
But the direct-to-consumer ad didn't come from Palo Alto-based Bridge Bio (Nasdaq: BBIO); instead it was produced by Pfizer ...
Revolving door is a VERY polite term for Patrizia Cavazzoni's moves. Then again, she has a 25-year history of picking Big Pharma over vulnerable patients. She'll fit right in with Scott Gottlieb.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results